EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study

Ray Manneh Kopp, Francesco Massari, Enrique Grande, Timothy J Schieber, Yüksel Ürün, Jindřich Kopecký, Javier Molina-Cerrillo, Umberto Basso, Jakub Kucharz, Thomas Büttner, Renate Pichler, Ondrej Fiala und 23 weitere

Cancer Immunology, Immunotherapy · 14.11.2025 · 74 (12)

DOI: 10.1007/s00262-025-04230-w ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 14.11.2025. Verfasst von Ray Manneh Kopp und 34 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Oncology, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alma Mater Studiorum - Università di Bologna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pembrolizumab has demonstrated efficacy in improving disease-free survival (DFS) and overall survival (OS) as adjuvant therapy in clear cell renal cell carcinoma (ccRCC) at a higher risk of recurrence. However, real-world data on its effectiveness and safety remain limited. This study evaluates DFS, OS and severe adverse events (SAEs) associated with adjuvant pembrolizumab in a multicenter international cohort.

Methods

This retrospective analysis included 311 ccRCC patients treated with adjuvant pembrolizumab across 40 hospitals in 12 countries from the ARON-1 dataset. Eligible patients had histologically confirmed ccRCC with high relapse risk and received up to 17 cycles of pembrolizumab. The primary objective was DFS, with OS and safety as secondary objectives. Kaplan–Meier survival estimates, Cox proportional hazards models and log-rank tests were used for statistical analysis.

Results

At a median follow-up of 15.4-month, 2-year OS and DFS rates were 95% and 69%, respectively. Recurrence occurred in 20% of patients, primarily in the lungs (11%) and bones (5%). DFS was significantly impaired in patients < 65 years (HR 2.14, p = 0.005), N1 disease (HR 5.42, p = 0.004) and sarcomatoid dedifferentiation (HR 2.54, p = 0.007). SAEs led to 19% treatment discontinuation, with colitis (4%), hypertransaminasemia (4%) and nephritis (3%) as the most common events. The study’s retrospective nature and short follow-up limit long-term outcome assessments.

Conclusions

This large real-world study confirms pembrolizumab’s effectiveness and manageable safety profile in the adjuvant setting for intermediate-high and high-risk ccRCC. Further research is needed to refine patient selection strategies and evaluate long-term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultChemotherapy, AdjuvantAged, 80 and overNeoplasm Recurrence, LocalFollow-Up Studies

Stichwörter der Autor:innen

ARON-1Adjuvant therapyImmune checkpoint inhibitorPembrolizumabReal-world dataRenal cell carcinoma

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Clinical Oncology, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia.
  • Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy. francesco.massari@aosp.bo.it.
  • Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. francesco.massari@aosp.bo.it.
  • Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain.
  • Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, Kansas city, USA.
  • Department of Medical Oncology, Faculty of Medicine, Ankara University, Türkiye; Westwood, Ankara, KS, 06620, USA.

Förderung

  • Alma Mater Studiorum - Università di Bologna

Zitieren

APA

Kopp, R. M., Massari, F., Grande, E., Schieber, T. J., Ürün, Y., Kopecký, J., Molina-Cerrillo, J., Basso, U., Kucharz, J., Büttner, T., Pichler, R., Fiala, O., Myint, Z. W., Galli, L., Buchler, T., Rizzo, M., Bolek, H., Bourlon, M. T., Conteduca, V., …, & Santoni, M. (2025). Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study. Cancer Immunology, Immunotherapy, 74(12). https://doi.org/10.1007/s00262-025-04230-w

Vancouver

Kopp RM, Massari F, Grande E, Schieber TJ, Ürün Y, Kopecký J, et al. Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study. Cancer Immunology, Immunotherapy. 2025;74(12). doi:10.1007/s00262-025-04230-w

BibTeX
@article{Kopp2025,
  author = {Kopp, Ray Manneh and Massari, Francesco and Grande, Enrique and Schieber, Timothy J and Ürün, Yüksel and Kopecký, Jindřich and Molina-Cerrillo, Javier and Basso, Umberto and Kucharz, Jakub and Büttner, Thomas and Pichler, Renate and Fiala, Ondrej and Myint, Zin W and Galli, Luca and Buchler, Tomas and Rizzo, Mimma and Bolek, Hatice and Bourlon, Maria T and Conteduca, Vincenza and Pinto, Alvaro and Rizzo, Alessandro and Rosellini, Matteo and Roviello, Giandomenico and Zgura, Anca and Mollica, Veronica and Partl, Antonia and Yildirim, Ahmet and Akova, Umut and Buti, Sebastiano and Monteiro, Fernando Sabino Marques and Soares, Andrey and Porta, Camillo and Bilen, Mehmet Asim and Li, Haoran and Santoni, Matteo},
  title = {Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  volume = {74},
  number = {12},
  doi = {10.1007/s00262-025-04230-w}
}
Kostenlos starten →